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Objective. To compare genital HSV shedding among HIV-positive and HIV-negative women. Methods.W o m e nw i t ha n dw i t h o u t
knownHIVinfection who delivered at theUniversity ofWashingtonMedical Center between 1989–1996had HSVserologiesdone
as part of clinical care. Genital swabs from HSV-2-seropositive women were evaluated by real-time quantitative HSV DNA PCR.
Results. HSV-2 seroprevalence was 71% and 30% among 75 HIV-positive and 3051 HIV-negative women, respectively, (P<. 001).
HSV was detected at delivery in the genital tract of 30.8% of HIV-seropositive versus 9.5% of HIV-negative women (RR = 3.2,
95% CI 1.6 to 6.5, P = .001). The number of virion copies shed per mL was similar (log3.54 for HIV positive versus 3.90 for
HIV negative, P = .99). Conclusions. Our study demonstrated that HIV-, HSV-2-coinfected women are more likely to shed HSV
at delivery.
1.Introduction
The rate of infant HIV infection in the USA has plummeted
withtheadvent ofroutineHIVtesting during pregnancyand
the availability of potent antiretroviral therapy. These public
health advances shift focus to prevention of other comorbid
conditions in HIV-infected women and their infants.
Herpes simplex virus type 2 infections are prevalent
among women and among persons with HIV infection. In
resource-limited settings with high HIV prevalence such as
the Central African Republic, HSV-2 antibody prevalence
among HIV-infected women is 91% [1]. Studies have
reported an increased risk of HIV infection in infants born
to HSV-2- and HIV-coinfected women or women who have
clinical genital herpes during pregnancy [2, 3]. The risk is
likelymediatedbyanincreaseinplasma and/ormucosalHIV
RNA during HSV reactivation [4]a n dm a yb ea b r o g a t e d
by antiretroviral therapy. Less attention has been given to
the potential for increased risk of neonatal herpes in infants
of coinfected women. Persons with HIV and HSV-2 have
increased rates of genital HSV reactivation, and, if they have
advanced immunosuppression, haveahigherrateofmucosal
HSV shedding [1, 5–7]. Because HSV genital shedding
during labor is the strongest risk factor for neonatal herpes
(relative risk > 300) [8], such HIV- and HSV-2-infected
women could be at increased risk for transmitting HSV to
their newborns. Neonatal herpes is a devastating disease
forinfants witha30%mortality rateinthecaseofadequately
treated disseminated disease [9].2 Infectious Diseases in Obstetrics and Gynecology
To assess the potential for HSV transmission to the
neonate among HIV-infected women, we compared rates
of HSV-2 infection and genital HSV shedding among HIV-
infected and HIV-negative women.
2.Methods
Women with known HIV infection who delivered at the
University of Washington Medical Center (UWMC), a
tertiary care referral center, between 1989 and 1996 were
included in the study. Additionally, women without known
HIV infection delivering at UWMC between 1995-96 were
included. All women were receiving comprehensive prenatal
care at UWMC or aﬃliated clinics. During the study period,
type-speciﬁc HSV serologies were included in routine pre-
natal care at our institution as part of a large, continuing
study of HSV in pregnancy approved by the University of
Washington Institutional Review Board [8]. Genital swabs
were obtained in a subset of women expected to deliver
vaginally as part of an ongoing study of infant exposure
to HSV during birth [8, 10, 11]. Genital secretions were
obtained from the labia majora and minora as well as
perianal and periclitoral areas with a dacron-tipped swab. A
second swab was collected from the ectocervix, endocervix,
and posteriorvaginal fornicesduring a speculumexam. HSV
was cultured from the genital secretions swab, as previously
reported [12]. The remaining sample was stored frozen for
later testing by PCR.
HIV serologic testing was performed using a commercial
enzyme-linkedimmunosorbent assay(Genetic SystemsHIV-
1/HIV-2 Plus O EIA, Bio-Rad, Redmond, WA) with Western
blot conﬁrmation for samples testing positive. Type-speciﬁc
HSVserostatus was determined with theUniversityofWash-
ington Western Blot [13]. Genital swabs were evaluated by
real-time quantitative HSV DNA polymerase chain reaction
(PCR) assay [14].
The prevalence of HSV-1 and HSV-2 antibodies and the
median and range of log copies of HSV shed were compared
among women with and without HIV infection. Categor-
ical variables were compared using chi-square or Fisher’s
exact test, and continuous variables were compared using
the Mann-Whitney test. Risk ratios with 95% conﬁdence
intervals(CIs)werealsocalculatedfor thediﬀerencebetween
these groups. A 2-sided P value of .05 or less was considered
statistically signiﬁcant. Statistical analyses were conducted
with SPSS for Windows, version 11.5.
3.Results
During the study interval, 75 known HIV seropositive
women had a total of 85 deliveries included in this analysis.
During 1995-1996, there were 3099 consecutive women
admitted to Labor and Delivery who were not known to
be HIV infected, and 3051 (98%) of these women had
HSV serology testing available; these were included as the
comparator group. The median age was 27 (range 17, 37)
for HIV-seropositive women and 29 (range 15, 49) for HIV-
negative women (P = .6). Among HIV-seropositive women,
50% were white, 21% black, and 29% other races. Among
HIV seronegative women, 46% were white, 34% black, and
20% were other races. Nulliparous women comprised 31%
of HIV-seropositive and 34% of HIV-seronegative women.
Among75HIV-seropositivewomen,71.2%hadantibody
to HSV-2 (28.7% to HSV-2 only and 42.5% to HSV-2
and HSV-1), 21.9% to HSV-1 only, and 6.8% were HSV
seronegative. In contrast, among 3051 HIV-seronegative
women, the HSV-2 seroprevalence rate was 30.3% (11.1%
seropositive for HSV-2 only and 19.2% seropositive for both
HSV-1 and HSV-2), while 50.6% were HSV-1 seropositive
only and 19.1% were HSV seronegative (P<. 001 for the
diﬀerence in frequency of HSV-2 antibody between HIV
seropositive and HIV seronegative women).
In a subset of HSV-2 seropositive women in the study,
the swab of genitalsecretions obtained at the time ofdelivery
was evaluated with HSV DNA PCR swabs. Among 26 HIV-
positive, HSV-2-seropositive women who were evaluated,
none had genitallesions, and all had swabs obtained forHSV
from genital secretions. Among 635 HIV-negative, HSV-
2-seropositive women who were evaluated, 13 had lesions
at delivery, and a swab for HSV was obtained from the
remaining 622 for HSV detection. Vaginal deliveries were
c o m m o ni nb o t hg r o u p so fH S V - 2 - i n f e c t e dw o m e nw i t h o u t
lesions as 79% of HIV-positive women and 96% of HIV-
negative women delivered vaginally.
Genital HSV was detected in 8 (30.8%) of 26 HIV-,
HSV-2-infected women at the time of delivery. Seven of
these women were HSV-2 PCR positive only, and one was
HSV-2 and HSV-1 positive by PCR swab. Speciﬁcally, HSV
DNA was detected in all 8 vulvar swabs, and in 4 of the
8 HSV was also detected in the cervical swabs. Among the
622 HIV seronegative women who had swabs taken for
PCR, 59 (9.5%) women had HSV detected. Of 59 women
who had HSV detected, 27 were positive both at vulva and
cervix, 24 only at the vulva, and 6 only at the cervix; an
additional 2 women were positive at the cervix but vulvar
swabs were not available. The risk of HSV detection among
HIV-seropositive women was 3.2-fold higher (95% CI 1.6
to 6.5, P = .001) than among HIV-seronegative women
(Table 1). Quantitative amount of HSV in the swabs did
not diﬀer signiﬁcantly between HIV-seropositive and HIV-
seronegative women with the median number of virion
copies per mL of log3.54 (range 2.85, 5.69) for HIV-positive
women versus log3.90 (range 2.17, 6.92) for HIV-negative
women (P = .99, Figure 1).
4.Discussion
OurstudyshowedthatHSV-2-andHIV-coinfectedpregnant
women were more likely to shed HSV at delivery than
their HIV negative counterparts. The quantitative amounts
of shedding did not diﬀer between HIV-positive and HIV-
negative women, perhaps reﬂecting the fact that all had
established HSV-2 infection. Viral shedding is the strongest
risk factor for transmission of HSV from the mother to the
neonate at birth [8]. While most transmissions to newborns
occur from pregnant women who have recently acquiredInfectious Diseases in Obstetrics and Gynecology 3
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Figure 1: HSV shedding by PCR in HIV-positive and HIV-negative
women at delivery.
genital HSV and have not developed a detectable antibody
response by the time of delivery, women with established
HSV-2infection are also atrisk fortransmitting HSVtotheir
neonate, but at a much lower rate [8].
Prior studies have addressed the role of HSV-2 in
increasing the risk of perinatal HIV transmission [15],
especially in Africa where HSV-2 infection aﬀects most
HIV-1-seropositive pregnant women [16]a n dh i g h l ya c t i v e
antiretroviral therapy is not universally used during preg-
nancy. Drake et al. [4] showed that genital ulcers were
associated with increased plasma HIV-1 RNA and increased
risk of intrapartum transmission of HIV and calculated
that 14% of HIV-1 transmissions were attributable to
maternal HSV-2 ulcers. The Cowan et al. study in Zimbabwe
suggested that 28% of intrapartum HIV transmissions are
potentiallyattributedtoprevalentmaternalHSV-2[16].Also
concerning this cohort is the additional 17% (29 of 193) of
initially HSV-2-seronegative women who subsequently sero-
converted to HSV-2 in the immediate peripartum period.
This suggests that a substantial number of women acquire
new HSV-2 infection peripartum, an event associated with
a 30–50% risk of HSV transmission to the neonate [17].
We are aware of a single-case report of HSV transmission
to the neonate from an HIV-infected woman [18]. In this
case,theHSVinfectionwas acquiredattheendofpregnancy.
Of note, this case was observed in a resource-rich setting,
underscoring that a diagnostic workup for neonatal HSV
is less likely to be routinely performed in the developing
world. To our knowledge, no systematic study evaluating the
incidence of neonatal HSV in resource-poor areas with high
HIV prevalence has been done.
Our study was limited by a relatively small number of
HIV-positive pregnant women. In addition, we focused on
women who are HSV-2 seropositive, who are at lesser risk
for transmitting neonatal herpes than women who acquire
genital HSV in late pregnancy. Further studies of the risk of
neonatal HSV among HIV-infected women should include
womenwhoareatriskforHSVacquisitionintheperipartum
period. Additionally, while routine heel sticks on infants
born to the presumed HIV-negative women during did
not reveal any unrecognized HIV infections, many of these
women did not have a conﬁrmed negative HIV test, as the
Table 1: HSV PCR positivity in vaginal swabs among HSV-2-
seropositive, HIV-positive and HIV-negative women at delivery.
Swab site HIV positive
women
HIV negative
women
Risk ratio,
95% CI P-value
Any site 8/26 (30.8%) 59/622 (9.5%) 3.2 (1.6, 6.5) .001
Cervix 4/25 (16.0%) 35/588 (6.0%) 2.7 (0.9, 7.3) .053
Vulva 8/24 (33.3%) 51/610 (8.4%) 4.0 (2.0, 8.1) <.001
Both
cervix and
vulva
4/23 (17.4%) 27/576 (4.7%) 3.7 (1.3, 10.3) .012
study was done prior to routine HIV testing in pregnancy
[19].
5.Conclusions
While suppressive therapy for HSV is recommended, and
utilized, for prevention of genital lesions at labor and
cesarean deliveries for women with a clinical history of
genital herpes [20], the impact of this approach on neonatal
HSV is unknown. The eﬀect of this strategy on the high
rate of HSV shedding in labor among HIV-infected, HSV-
2-seropositive women has not been studied. In addition,
antiviral therapy for HSV is used infrequently in resource-
poor countries. Suppressive therapy with acyclovir and
valacyclovir has been shown to reduce plasma and genital
HIV RNA levels by 0.25–0.50log but not to impact the risk
of sexual transmission of HIV [21–23]. Ongoing studies
will evaluate whether valacyclovir can reduce the risk of
mother to child HIV transmission during late pregnancy, the
intrapartum period, and breastfeeding.
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